Pentoxifylline in heart failure: a meta-analysis of clinical trials.

摘要: Background Pentoxifylline possess antiinflammatory and rheological properties has been tested in heart failure (HF). Methods A comprehensive search was performed from 1980 until July 2013 PubMed, to identify randomized controlled trials evaluating pentoxifylline versus placebo HF, determine impact on mortality. Search strategy is as follows: “Pentoxifylline” AND “heart” “trial”. Study selection of six mortality outcome. Then, we conducted a meta-analysis HF. Determination Mantel–Haenszel fixed effect random-effect pooled odds ratios for all-cause corresponding 95% confidence intervals. Results Data total 221 patients with LVEF ≤40% were included this analysis. Pentoxifylline 1200 mg per day administered during 6 months, except one study (administered 1 month severe acute HF). The use not significantly associated reduction HF individual studies. data including showed nearly fourfold (5.4% vs. 18.3%; OR 0.29; CI 0.12–0.74; P < 0.01) homogenous results (I² 0%). Conclusion A suggested significant decrease the group.